ELAVL1 and breast cancer: This study identifies ARID1A as a novel HuR target and provides evidence for a pivotal role of the HuR/ARID1A axis in breast cancer radioresistance, thereby supporting the potential therapeutic targeting to enhance radiotherapy in breast cancer.